PROMEDIGEN is a first-in-class biotechnology company focusing on the treatment of cancer and neurodegenerative disorders.
Proteins control the metabolism, growth, and cell division through various types of post-translational modifications (PTMs). Abnormal PTMs may ruin many cellular processes including signal transduction, leading to serious diseases such as cancer and neurodegenerative disorders. While significant advances have been made to understand PTMs and their effect on protein-protein interactions (PPIs) and cellular signaling pathways, this area remains technically challenging. This, in turn, makes it difficult to elucidate the causes of various diseases and to find effective treatments.
PROMEDIGEN has developed a unique, proprietary technology platform for site-specific introduction of PTMs. This technology enables production of abnormally modified proteins that are associated with a variety of serious diseases including cancer and dementia. Using this novel protein engineering platform, PROMEDIGEN is making breakthroughs toward the development of innovative, first-in-class drugs. Specifically, one of the key goals is to address drug resistance in cancer.
PROMEDIGEN is advancing a pipeline containing multiple cancer-specific targets that have previously been considered intractable. Utilizing its groundbreaking modified protein-based PPI drug discovery platform, PROMEDIGEN is growing into a first-in-class biotech company leading the development of new, innovative treatments for cancer and neurodegenerative disorders.